Jean L. Grem

18.7k total citations · 1 hit paper
168 papers, 5.9k citations indexed

About

Jean L. Grem is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean L. Grem has authored 168 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 55 papers in Molecular Biology and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean L. Grem's work include Colorectal Cancer Treatments and Studies (63 papers), Cancer Treatment and Pharmacology (47 papers) and Pancreatic and Hepatic Oncology Research (21 papers). Jean L. Grem is often cited by papers focused on Colorectal Cancer Treatments and Studies (63 papers), Cancer Treatment and Pharmacology (47 papers) and Pancreatic and Hepatic Oncology Research (21 papers). Jean L. Grem collaborates with scholars based in United States, Malaysia and Ukraine. Jean L. Grem's co-authors include Richard H. Wilson, Carmen J. Allegra, Chris H. Takimoto, Rebecca R. Thomas, Mary Quinn, Tanya Lehky, Mary Kay Floeter, Paul H. Fischer, Susan A. King and J. Michael Hamilton and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Hepatology.

In The Last Decade

Jean L. Grem

166 papers receiving 5.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B

2009 535 citations Jean L. Grem et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jean L. Grem United States	41	3.0k	1.8k	970	892	722	168	5.9k
Muhammad Wasif Saif United States	44	4.6k 1.5×	1.9k 1.1×	1.4k 1.5×	995 1.1×	408 0.6×	412	7.9k
Jean‐Pierre Armand France	42	3.7k 1.2×	2.6k 1.5×	2.1k 2.1×	514 0.6×	299 0.4×	161	6.9k
M. E. Scheulen Germany	36	2.6k 0.9×	2.3k 1.3×	1.2k 1.2×	302 0.3×	390 0.5×	178	5.5k
Érick Gamelin France	42	4.2k 1.4×	1.7k 1.0×	1.0k 1.1×	213 0.2×	512 0.7×	138	6.3k
Scott Wadler United States	43	4.5k 1.5×	2.0k 1.1×	1.9k 2.0×	517 0.6×	628 0.9×	192	8.1k
R. Bugat France	42	4.4k 1.4×	1.7k 0.9×	1.6k 1.7×	320 0.4×	730 1.0×	181	6.5k
Dirk Strumberg Germany	42	3.1k 1.0×	3.5k 2.0×	1.6k 1.6×	331 0.4×	698 1.0×	141	7.4k
J Carmichael United Kingdom	39	4.8k 1.6×	2.3k 1.3×	1.5k 1.5×	359 0.4×	895 1.2×	76	7.3k
Hideo Ishitsuka Japan	35	3.2k 1.1×	1.9k 1.1×	981 1.0×	446 0.5×	453 0.6×	85	5.7k
Bridget A. Robinson New Zealand	37	2.0k 0.7×	1.3k 0.8×	697 0.7×	400 0.4×	222 0.3×	140	4.4k

Countries citing papers authored by Jean L. Grem

Since Specialization

Citations

This map shows the geographic impact of Jean L. Grem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean L. Grem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean L. Grem more than expected).

Fields of papers citing papers by Jean L. Grem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean L. Grem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean L. Grem. The network helps show where Jean L. Grem may publish in the future.

Co-authorship network of co-authors of Jean L. Grem

This figure shows the co-authorship network connecting the top 25 collaborators of Jean L. Grem. A scholar is included among the top collaborators of Jean L. Grem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean L. Grem. Jean L. Grem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Chi, Jean L. Grem, Kelsey Klute, et al.. (2021). The Phase I Results of a Phase 1/2 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5-Fluorouracil, Mitomycin and BMX-001. International Journal of Radiation Oncology*Biology*Physics. 111(3). S103–S103. 1 indexed citations

Law, Henry C.-H., Fangfang Qiao, Diane Costanzo-Garvey, et al.. (2019). The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Clinical Cancer Research. 26(5). 1065–1076. 44 indexed citations

Tadros, Saber, Surendra K. Shukla, Ryan J. King, et al.. (2017). De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. Cancer Research. 77(20). 5503–5517. 160 indexed citations

Clausen, Thomas Mandel, Marina Ayres Pereira, Nader Al Nakouzi, et al.. (2016). Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. Molecular Cancer Research. 14(12). 1288–1299. 46 indexed citations

Elkahwaji, Johny E., Elizabeth Reed, Apar Kishor Ganti, et al.. (2009). Phase I study of imatinib in combination with gemcitabine and capecitabine. Journal of Clinical Oncology. 27(15_suppl). e13523–e13523. 1 indexed citations

Grem, Jean L.. (2005). The saltz article reviewed. 19(9). 4 indexed citations

Leonard, Gregory D., M. A. Wright, Mary Quinn, et al.. (2005). Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 5(1). 116–116. 135 indexed citations

Thomas, Rebecca R., Mary Quinn, Barbara Schüler, & Jean L. Grem. (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 97(9). 2301–2307. 91 indexed citations

Grem, Jean L., et al.. (1999). Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochemical Pharmacology. 58(3). 477–486. 48 indexed citations

10.

Grem, Jean L., et al.. (1998). The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer.. Oncology Reports. 5(3). 559–67. 16 indexed citations

11.

Grem, Jean L.. (1998). Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches. Cancer treatment and research. 98. 293–338. 3 indexed citations

12.

Grem, Jean L., et al.. (1995). The role of interferon-α as a modulator of fluorouracil and leucovorin. European Journal of Cancer. 31(7-8). 1316–1320. 11 indexed citations

13.

Grem, Jean L., J C Drake, & Carmen J. Allegra. (1993). Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography. Anti-Cancer Drugs. 4(5). 545–554. 1 indexed citations

14.

Blaney, Susan M., et al.. (1993). Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochemical Pharmacology. 45(7). 1493–1501. 13 indexed citations

15.

Grem, Jean L., Nanette McAtee, Frank M. Balis, et al.. (1993). A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer. 72(3). 663–668. 29 indexed citations

16.

Bailey, Howard H., George Wilding, Kendra D. Tutsch, et al.. (1992). A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer Chemotherapy and Pharmacology. 30(4). 297–302. 2 indexed citations

17.

Grem, Jean L. & Carmen J. Allegra. (1990). Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.. PubMed. 50(22). 7279–84. 17 indexed citations

18.

Grem, Jean L., Susan A. King, Bruce D. Cheson, B Leyland-Jones, & R. Wittes. (1989). Pentostatin in Hairy Cell Leukemia: Treatment by the Special Exception Mechanism. JNCI Journal of the National Cancer Institute. 81(6). 448–453. 28 indexed citations

19.

Grem, Jean L., DeWayne Shoemaker, Nicholas J. Petrelli, & H. O. Douglass. (1987). Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.. PubMed. 71(11). 1122–1122. 13 indexed citations

20.

Metzger, W. James, et al.. (1984). C1 INH deficiency and angioedema: a spectrum of disease. Part one.. PubMed. 52(4). 269–71. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact